HN2003000038A - Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico - Google Patents

Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Info

Publication number
HN2003000038A
HN2003000038A HN2003000038A HN2003000038A HN2003000038A HN 2003000038 A HN2003000038 A HN 2003000038A HN 2003000038 A HN2003000038 A HN 2003000038A HN 2003000038 A HN2003000038 A HN 2003000038A HN 2003000038 A HN2003000038 A HN 2003000038A
Authority
HN
Honduras
Prior art keywords
phenyl
replaced
antranilico
esteres
hydroxamate
Prior art date
Application number
HN2003000038A
Other languages
English (en)
Inventor
Stephen Douglas Barret
Michael David Kaufman
Gordon William Rewcastle
Julie Ann Spicer
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of HN2003000038A publication Critical patent/HN2003000038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A ESTERES OXGENADOS DE DERIVADOS DE ACIDO (4-FENIL-SUSTITUIDO)AMINOBENZOHIDROXAMICO, A COMPOSICIONES FARMACEUTICAS Y A METODOS PARA USARLOS.
HN2003000038A 2002-01-23 2003-01-21 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico HN2003000038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35110602P 2002-01-23 2002-01-23

Publications (1)

Publication Number Publication Date
HN2003000038A true HN2003000038A (es) 2003-01-21

Family

ID=27613459

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2003000038A HN2003000038A (es) 2002-01-23 2003-01-21 Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico

Country Status (14)

Country Link
US (1) US6770778B2 (es)
EP (1) EP1467965A1 (es)
JP (1) JP2005515251A (es)
AR (1) AR038212A1 (es)
BR (1) BR0307071A (es)
CA (1) CA2472367A1 (es)
DO (1) DOP2003000556A (es)
HN (1) HN2003000038A (es)
MX (1) MXPA04005528A (es)
PA (1) PA8563901A1 (es)
PE (1) PE20030925A1 (es)
TW (1) TW200302084A (es)
UY (1) UY27618A1 (es)
WO (1) WO2003062189A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415710A (pt) 2003-10-21 2006-12-19 Warner Lambert Co formas polimórficas de n-[(r)-2,3-dihidróxi-propóxi]-3,4-diflúor-2-(2-flúor-4-io dofenilamino)-benzamida
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
JP2007513967A (ja) * 2003-12-11 2007-05-31 セラヴァンス， インコーポレーテッド 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
US8101799B2 (en) * 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
EP1934174B1 (en) 2005-10-07 2011-04-06 Exelixis, Inc. Azetidines as mek inhibitors for the treatment of proliferative diseases
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
EP2207541B1 (en) * 2007-10-05 2014-10-29 Sanofi-Aventis Deutschland GmbH Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain
JP5746630B2 (ja) 2008-11-10 2015-07-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 置換スルホンアミドフェノキシベンズアミド
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
WO2011047795A1 (en) 2009-10-21 2011-04-28 Bayer Schering Pharma Aktiengesellschaft Substituted benzosulphonamides
US8962606B2 (en) 2009-10-21 2015-02-24 Bayer Intellectual Property Gmbh Substituted benzosulphonamides
US20120263714A1 (en) 2009-10-21 2012-10-18 Bayer Intellectual Property Gmbh Substituted halophenoxybenzamide derivatives
MX340392B (es) 2010-02-25 2016-07-06 Dana Farber Cancer Inst Inc Mutaciones del protooncogen de serina/treonina-proteina cinasa b-raf (braf) que confieren resistencia a los inhibidores del protooncogen de serina/treonina-proteina cinasa b-raf.
BR112012022801B8 (pt) 2010-03-09 2019-10-29 Dana Farber Cancer Inst Inc método de identificar um indivíduo que tem câncer que é provável beneficiar-se do tratamento com uma terapia de combinação com um inibidor de raf e um segundo inibidor e uso de um inibidor de raf e um segundo inibidor para a fabricação de um medicamento para tratar câncer
WO2012055953A1 (en) 2010-10-29 2012-05-03 Bayer Pharma Aktiengesellschaft Substituted phenoxypyridines
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
MX2014014097A (es) 2012-05-31 2015-04-13 Bayer Pharma AG Biomarcadores para determinar la respuesta eficaz de tratamientos en pacientes de carcinoma hepatocelular (chc).
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
JP2016034900A (ja) * 2012-11-26 2016-03-17 中外製薬株式会社 ５−置換−２−フェニルアミノ−ベンズアミド類の製造方法
CN103508965B (zh) * 2013-09-27 2015-04-08 天津大学 一种二苯西平类衍生物的合成方法
CN105646438A (zh) * 2015-12-22 2016-06-08 天津大学 一种缩酮类糖醇基小分子凝胶因子及其制备方法和应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2082171A (en) 1933-05-24 1937-06-01 Winthrop Chem Co Inc Basically substituted amino acridine derivatives
NL62219C (es) 1945-05-07
US2553914A (en) 1948-03-22 1951-05-22 Ward Blenkinsop & Co Ltd Substituted diphenylamine 2-monocarboxylic acids and the production thereof
US3781358A (en) 1968-05-29 1973-12-25 E Anderson Intermediates for preparing acridines
CH541608A (de) 1970-11-06 1973-09-15 Ciba Geigy Ag Verfahren zur Herstellung von Nitrodiphenylaminen und deren Verwendung
US4510139A (en) 1984-01-06 1985-04-09 Sterling Drug Inc. Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity
DE3608726A1 (de) 1986-03-15 1987-09-17 Hoechst Ag Verwendung aminosubstituierter benzoesaeuren als heilmittel gegen diarrhoe und arzneimittel auf basis dieser verbindungen
US5155110A (en) 1987-10-27 1992-10-13 Warner-Lambert Company Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition
US5068250A (en) 1988-09-29 1991-11-26 Trustees Of University Of Pennsylvania Irreversible ligands for nonsteroidal antiinflammatory drug and prostaglandin binding sites
AU4090093A (en) 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5525625A (en) 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
WO1997007790A1 (en) 1995-08-28 1997-03-06 Interlab Corporation Pharmaceutical compositions for the treatment of infectious diseases
IL118657A0 (en) 1996-06-14 1996-10-16 Arad Dorit Inhibitors for picornavirus proteases
US6251943B1 (en) 1997-02-28 2001-06-26 Warner-Lambert Company Method of treating or preventing septic shock by administering a MEK inhibitor
US6310060B1 (en) 1998-06-24 2001-10-30 Warner-Lambert Company 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors
CN1163475C (zh) 1997-07-01 2004-08-25 沃尼尔·朗伯公司 4-溴或4-碘苯基氨基苯氧肟酸衍生物及其作为mek抑制剂的用途
ES2274572T3 (es) * 1997-07-01 2007-05-16 Warner-Lambert Company Llc Derivados de acido 2-(4-bromo- o 4-yodo-fenilamino) benzoico y su uso como inhibidor de mek.
ATE239000T1 (de) 1997-10-28 2003-05-15 Warner Lambert Co 7-substituierte chinazolin-2,4-dionen verwendbar als antibakterielle mittel
JP2002534380A (ja) * 1999-01-07 2002-10-15 ワーナー−ランバート・カンパニー Ｍｅｋ阻害剤による喘息の治療
BR9916857A (pt) 1999-01-13 2001-12-04 Warner Lambert Co 4 heteroaril diarilaminas
ES2461854T3 (es) 2000-07-19 2014-05-21 Warner-Lambert Company Llc Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos

Also Published As

Publication number Publication date
TW200302084A (en) 2003-08-01
BR0307071A (pt) 2004-12-28
UY27618A1 (es) 2003-08-29
PE20030925A1 (es) 2003-10-29
EP1467965A1 (en) 2004-10-20
JP2005515251A (ja) 2005-05-26
DOP2003000556A (es) 2003-10-31
US6770778B2 (en) 2004-08-03
WO2003062189A1 (en) 2003-07-31
MXPA04005528A (es) 2005-03-23
AR038212A1 (es) 2005-01-05
PA8563901A1 (es) 2003-09-05
CA2472367A1 (en) 2003-07-31
US20030232889A1 (en) 2003-12-18

Similar Documents

Publication Publication Date Title
HN2003000038A (es) Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico
HN2003000044A (es) Esteres hidroxamato del acido n - (4-fenil sustituido)-antranilico.
ECSP095220A (es) Derivados de n-fenil-2-pirimidin-amina
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
NO20044744L (no) Karbaminsyreforbindelser omfattende et piperazinledd som HDASinbibitorer
EA200500203A1 (ru) Новый способ синтеза и новая кристаллическая форма агомелатина и фармацевтические композиции, которые её содержат
IS7714A (is) Lyfjasamsetningar úr módafíníl
NO20090175L (no) Stabile laquinimod sammensetninger
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
BR0307564A (pt) Derivados de nicotinamida úteis como inibidores de pde4
BRPI0518904A2 (pt) formulaÇÕes de nepafenac tàpicas
ATE440833T1 (de) Antithrombotische diamide
CO5590918A2 (es) Formulaciones
PA8559401A1 (es) Sales de acido succinico de 5,7,14-triazatetraciclo (10.3.1.0 2,11.0 4, 9)-hexadeca-2 (11),3,5,7,9-pentaeno y composiciones farmaceuticas de las mismas.
BRPI0410727A (pt) composto, composição farmacêutica, e, uso de um composto
IS2707B (is) Nýjar lyfjasamsetningar úr módafíníli
HN2002000198A (es) Composiciones farmaceuticas de amlodipina y atorvastatina
SV2004001481A (es) Derivados de nicotinamida utiles como inhibidores de pde4" ref. pc22065a
ITFI20050041A1 (it) Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono
BR0312522A (pt) Método para a preparação de trombina inativada por vìrus, trombina, formulação farmacêutica, e, kit farmacêutico
PA8661701A1 (es) Tiazolidinonas, su preparacion y su uso como medicamento
ATE253359T1 (de) Antithrombotische mittel
DE69828522D1 (de) Antithrombotische mittel
CY1107277T1 (el) Βενζισοξαζολες